{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:32:03Z","timestamp":1783535523315,"version":"3.55.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Renal Replacement Therapy"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1053\/j.arrt.2003.11.007","type":"journal-article","created":{"date-parts":[[2004,1,16]],"date-time":"2004-01-16T16:42:34Z","timestamp":1074271354000},"page":"24-40","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacological strategies for kidney function preservation: are there differences by ethnicity?"],"prefix":"10.1053","volume":"11","author":[{"given":"Jay","family":"Lakkis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.arrt.2003.11.007_BIB1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population","volume":"41","author":"Coresh","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB2","series-title":"Annual Data Report","year":"2002"},{"key":"10.1053\/j.arrt.2003.11.007_BIB3","first-page":"249","article-title":"African American Study of Kidney Disease and hypertension (AASK)\u2014Clinical trial update","volume":"8","author":"Agodoa","year":"1998","journal-title":"Ethn Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB4","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ki.1997.260","article-title":"Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study","volume":"51","author":"Hunsicker","year":"1997","journal-title":"Kidney Int"},{"key":"10.1053\/j.arrt.2003.11.007_BIB5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM199601043340103","article-title":"Blood pressure and end-stage renal disease in men","volume":"334","author":"Klag","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.290.2.199","article-title":"Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988\u20132000","volume":"290","author":"Hajjar","year":"2003","journal-title":"JAMA"},{"key":"10.1053\/j.arrt.2003.11.007_BIB7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/01.HYP.25.3.305","article-title":"Prevalence of hypertension in the US adult population","volume":"25","author":"Burt","year":"1995","journal-title":"Hypertension"},{"key":"10.1053\/j.arrt.2003.11.007_BIB8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/archinte.161.9.1207","article-title":"Prevalence of high blood pressure and elevated serum creatinine level in the United States","volume":"161","author":"Coresh","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0272-6386(96)90380-7","article-title":"Prevalence of hypertension in 1,795 subjects with chronic renal disease: The modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group","volume":"28","author":"Buckalew","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB10","series-title":"National Kidney and Urologic Diseases Information Clearinghouse","year":"2003"},{"key":"10.1053\/j.arrt.2003.11.007_BIB11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/diacare.24.2.412","article-title":"The continuing increase of diabetes in the US","volume":"24","author":"Mokdad","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1053\/j.arrt.2003.11.007_BIB12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/diacare.21.4.518","article-title":"Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988\u20131994","volume":"21","author":"Harris","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1053\/j.arrt.2003.11.007_BIB13","series-title":"National Diabetes Statistics fact sheet","year":"2002"},{"key":"10.1053\/j.arrt.2003.11.007_BIB14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/oby.2000.79","article-title":"Body mass index and the prevalence of hypertension and dyslipidemia","volume":"8","author":"Brown","year":"2000","journal-title":"Obes Res"},{"key":"10.1053\/j.arrt.2003.11.007_BIB15","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.288.14.1723","article-title":"Prevalence and trends in obesity among US adults, 1999\u20132000","volume":"288","author":"Flegal","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.arrt.2003.11.007_BIB16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.1999.tb07788.x","article-title":"Mechanisms of hypertension and kidney disease in obesity","volume":"892","author":"Hall","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/j.arrt.2003.11.007_BIB17","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/archinte.1986.00360180095016","article-title":"Renal disease in patients with massive obesity","volume":"146","author":"Kasiske","year":"1986","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB18","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1161\/01.CIR.0000033219.24717.52","article-title":"Influence of leptin on arterial distensibility","volume":"106","author":"Singhal","year":"2002","journal-title":"Circulation"},{"key":"10.1053\/j.arrt.2003.11.007_BIB19","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1053\/j.arrt.2003.11.007_BIB20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/archinte.163.5.525","article-title":"Management of high blood pressure in African Americans","volume":"163","author":"Douglas","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB21","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0272-6386(00)70054-0","article-title":"Chronic proteinuric nephropathies","volume":"35","author":"Ruggenenti","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB22","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-93-5-676","article-title":"Renal function during long-term treatment of hypertension with minoxidil","volume":"93","author":"Mitchell","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/01.CIR.40.6.893","article-title":"The value of aggressive therapy in the hypertensive patient with azotemia","volume":"40","author":"Mroczek","year":"1969","journal-title":"Circulation"},{"key":"10.1053\/j.arrt.2003.11.007_BIB24","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.V74556","article-title":"Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study","volume":"7","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.arrt.2003.11.007_BIB26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.V122218","article-title":"Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study","volume":"12","author":"Ruilope","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.arrt.2003.11.007_BIB27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/01.HYP.30.3.428","article-title":"Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group","volume":"30","author":"Hebert","year":"1997","journal-title":"Hypertension"},{"key":"10.1053\/j.arrt.2003.11.007_BIB28","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1001\/jama.1992.03490210067037","article-title":"Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group","volume":"268","author":"Walker","year":"1992","journal-title":"JAMA"},{"key":"10.1053\/j.arrt.2003.11.007_BIB29","first-page":"141","article-title":"Maximizing cardiorenal benefit in the management of hypertension","volume":"1","author":"Bakris","year":"1999","journal-title":"J Clin Hypertens (Greenwich.)"},{"key":"10.1053\/j.arrt.2003.11.007_BIB30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/BF00542218","article-title":"Pharmacokinetics of hydrochlorothiazide in relation to renal function","volume":"24","author":"Niemeyer","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.arrt.2003.11.007_BIB31","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"issue":"suppl","key":"10.1053\/j.arrt.2003.11.007_BIB32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/ndt\/16.suppl_1.82","article-title":"Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure","volume":"16","author":"Mora-Macia","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.arrt.2003.11.007_BIB33","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/01.HYP.31.5.1088","article-title":"Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives","volume":"31","author":"Weir","year":"1998","journal-title":"Hypertension"},{"key":"10.1053\/j.arrt.2003.11.007_BIB34","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/01.HYP.30.3.422","article-title":"Salt and blood pressure responses to calcium antagonism in hypertensive patients","volume":"30","author":"Weir","year":"1997","journal-title":"Hypertension"},{"key":"10.1053\/j.arrt.2003.11.007_BIB35","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/archinte.1990.00040031707020","article-title":"A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks","volume":"150","author":"Saunders","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB36","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.arrt.2003.11.007_BIB37","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.arrt.2003.11.007_BIB38","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial results. Ramipril efficacy in nephropathy","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.arrt.2003.11.007_BIB39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1524-6175.2003.01924.x","article-title":"Current concepts of pharmacotherapy in hypertension: The African American Study of Kidney Disease and Hypertension (AASK) trial: What more have we learned?","volume":"5","author":"Sica","year":"2003","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1053\/j.arrt.2003.11.007_BIB40","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/archinte.162.14.1636","article-title":"Successful blood pressure control in the African American Study of Kidney Disease and Hypertension","volume":"162","author":"Wright","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/0895-7061(96)00056-8","article-title":"Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study","volume":"9","author":"Lee","year":"1996","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.arrt.2003.11.007_BIB42","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.arrt.2003.11.007_BIB43","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(95)91747-0","article-title":"Prevention of diabetic renal disease with special reference to microalbuminuria","volume":"346","author":"Mogensen","year":"1995","journal-title":"Lancet"},{"key":"10.1053\/j.arrt.2003.11.007_BIB44","series-title":"Mechanisms and Clinical Management of Chronic Renal Failure","first-page":"211","article-title":"Diabetic nephropathy","author":"Mogensen","year":"2000"},{"key":"10.1053\/j.arrt.2003.11.007_BIB45","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM198402093100605","article-title":"Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes","volume":"310","author":"Mogensen","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB46","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2337\/diacare.23.6.754","article-title":"Health care and health status and outcomes for patients with type 2 diabetes","volume":"23","author":"Harris","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1053\/j.arrt.2003.11.007_BIB47","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Irbesartan Microalbuminuria Type II Diabetes in Hypertensive Patients (IRMA II)","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB48","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL)","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB49","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Reno-protective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB50","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.arrt.2003.11.007_BIB52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.arrt.2003.11.007_BIB53","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","article-title":"Outcome results of the fosinopril versus amlodipine cardiovascular events trial (FACET) in patients with hypertension and NIDDM","volume":"21","author":"Tatti","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1053\/j.arrt.2003.11.007_BIB54","first-page":"333","article-title":"Representation of blacks, women, and the very elderly (aged > or = 80) in 28 major randomized clinical trials","volume":"9","author":"Hall","year":"1999","journal-title":"Ethn Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/01.CIR.100.1.33","article-title":"Effect of hypertension on mortality in Pima Indians","volume":"100","author":"Sievers","year":"1999","journal-title":"Circulation"},{"key":"10.1053\/j.arrt.2003.11.007_BIB56","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/01.HYP.29.2.641","article-title":"Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group","volume":"29","author":"Lazarus","year":"1997","journal-title":"Hypertension"},{"key":"10.1053\/j.arrt.2003.11.007_BIB57","doi-asserted-by":"crossref","first-page":"S-21","DOI":"10.7326\/0003-4819-135-2-200107170-00003","article-title":"Summaries for patients. Using a type of blood pressure medicine, angiotensin-converting enzyme inhibitors, to prevent worsening of kidney disease unrelated to diabetes","volume":"135","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB58","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0272-6386(00)70018-7","article-title":"Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease","volume":"35","author":"Kshirsagar","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.arrt.2003.11.007_BIB60","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1681\/ASN.V1081793","article-title":"Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States","volume":"10","author":"Obrador","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.arrt.2003.11.007_BIB61","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0272-6386(00)70334-9","article-title":"Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure","volume":"35","author":"Hayashi","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB62","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/ndt\/15.9.1425","article-title":"Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure","volume":"15","author":"McMahon","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.arrt.2003.11.007_BIB63","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0272-6386(97)90335-8","article-title":"Cardiovascular effects of recombinant human erythropoietin in predialysis patients","volume":"29","author":"Portoles","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB64","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB65","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0272-6386(89)80149-0","article-title":"The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function","volume":"14","author":"Kleinman","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB66","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1172\/JCI118646","article-title":"Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure","volume":"97","author":"Marrades","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1053\/j.arrt.2003.11.007_BIB67","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0272-6386(95)90122-1","article-title":"Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients","volume":"25","author":"Revicki","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB68","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0272-6386(12)80671-8","article-title":"Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients","volume":"24","author":"Roth","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.arrt.2003.11.007_BIB69","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000190270","article-title":"Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients","volume":"77","author":"Kuriyama","year":"1997","journal-title":"Nephron"},{"key":"10.1053\/j.arrt.2003.11.007_BIB70","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ndt\/16.2.307","article-title":"Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients","volume":"16","author":"Jungers","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.arrt.2003.11.007_BIB71","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1053\/ajkd.2003.50140","article-title":"A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease","volume":"41","author":"Bianchi","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"suppl 3","key":"10.1053\/j.arrt.2003.11.007_BIB72","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease","volume":"41","year":"2003","journal-title":"Am J Kidney Dis"}],"container-title":["Advances in Renal Replacement Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107344490300089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107344490300089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T01:01:18Z","timestamp":1623632478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107344490300089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S107344490300089X"],"URL":"https:\/\/doi.org\/10.1053\/j.arrt.2003.11.007","relation":{},"ISSN":["1073-4449"],"issn-type":[{"value":"1073-4449","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}